PlainRecalls
FDA Drug Moderate Class II Terminated

Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL Single Dose Vials (NDC 0641-6043-01), 25 vials/shelf-pack (NDC 0641-6043-25), For IM Use Only, Rx only, Manufactured by: WEST-WARD Eatontown, NJ 07724 USA.

Reported: January 22, 2020 Initiated: December 17, 2019 #D-0658-2020

Product Description

Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL Single Dose Vials (NDC 0641-6043-01), 25 vials/shelf-pack (NDC 0641-6043-25), For IM Use Only, Rx only, Manufactured by: WEST-WARD Eatontown, NJ 07724 USA.

Reason for Recall

Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)

Details

Units Affected
25,817 shelf packs/25 vials per pack
Distribution
Nationwide within the United States
Location
Cherry Hill, NJ

Frequently Asked Questions

What product was recalled?
Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL Single Dose Vials (NDC 0641-6043-01), 25 vials/shelf-pack (NDC 0641-6043-25), For IM Use Only, Rx only, Manufactured by: WEST-WARD Eatontown, NJ 07724 USA.. Recalled by Hikma Pharmaceuticals USA Inc.. Units affected: 25,817 shelf packs/25 vials per pack.
Why was this product recalled?
Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)
Which agency issued this recall?
This recall was issued by the FDA Drug on January 22, 2020. Severity: Moderate. Recall number: D-0658-2020.